*ST苏吴: 江苏吴中医药发展股份有限公司关于股票交易暨退市风险提示公告

Core Viewpoint - The company faces significant risks of delisting due to major violations and financial issues, as indicated by recent regulatory actions and financial report evaluations [1][2][3] Group 1: Delisting Risk - The company has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), which may lead to mandatory delisting if major violations are confirmed [1][3] - The company's stock has been under delisting risk warning since July 14, 2025, due to potential major violations [1][3] Group 2: Financial Reporting Issues - The company's 2024 financial report received a disclaimer of opinion from the auditing firm, triggering delisting risk warnings under the Shanghai Stock Exchange rules [1][2] - The company is also facing additional risk warnings due to internal control issues highlighted in the 2024 financial report [2] Group 3: Other Operational Risks - The company is involved in a legal arbitration case with a partner, which may affect its ability to continue sales of certain products [2] - There are indications of non-operational fund occupation by related parties, which has led to further risk warnings [2]